Phenotyping the Chronic Respiratory Diseases (CRD) in Ho Chi Minh City, Vietnam

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

610 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-08-31

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

World Health Organization (WHO) considers chronic respiratory disease (CRD) as one of its four priorities. These diseases include asthma and rhinitis, chronic obstructive pulmonary diseases (COPD), occupational lung diseases, sleep apnoea syndromes, pulmonary hypertension, bronchiectasis and interstitial lung diseases. They constitute a serious public health problem in all countries throughout the world, in particular in low and middle income countries and in deprived populations. Hundreds of millions of people of all ages, in all countries of the world, are affected by chronic respiratory diseases. More than 50% of them live in low and middle income countries. Over 90% of deaths and the complete inability, due to CRDs occur in countries with low or middle incomes.

The main causes of CRD are: tobacco smoke, occupational factors, indoor air pollution and outdoor air pollution, allergens, sequelae of respiratory infections such as tuberculosis.

More than 30% of the population of Ho Chi Minh City (HCMC) could develop a CRD. In fact, 15% of children and 7% of adults could become asthma and 6% of the population could become COPD due to smoking. Children exposed to fumes from biomass burning, early in their life, seem to have a higher risk to develop COPD. The high level of air pollution in HCMC could aggravate asthma / COPD. Populations combining the rural risk (exposure to smoke from biomass) and the urban risk (smoking, pollution) may develop COPD much earlier (before age 40). Among the 9 million people in HCMC, 50% of the population is rural origin. Within this population, parasites could play a protective role against the risk of allergic asthma and consequently, the better control of helminthiasis among urban population, may result in allergic diseases such as asthma and anaphylaxis. Finally, the sequelae of tuberculosis (incidence is 200/100000) could participate to the morbidity of COPD / CRD.

Study granted by the ARES-CUD ("Comission universitaire au développement")

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating the Relationship Between Environmental Risk Factors in Housing Types and Chronic Respiratory Diseases in Ho Chi Minh City

NCT02898129

Chronic Respiratory Diseases

COMPLETED NA

Development of Predictive Biomarkers for the Diagnosis and Treatment of Asthma and COPD in Vietnam.

NCT04232579

Chronic Obstructive Respiratory Diseases

UNKNOWN

Chronic Respiratory Disease Burden in Bangladesh

NCT04851808

Chronic Respiratory Disease COPD

UNKNOWN

Mitigating Chronic Respiratory Disease Through the Lens of Multi-Morbidity

NCT07050823

Chronic Obstructive Pulmonary Disease (COPD) Asthma Preserved Ratio Impaired Spirometry

RECRUITING

Association Analysis for Chronic Diseases Based on Resident Health Records by Using Big Data Methods

NCT03279822

Chronic Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Respiratory Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic respiratory disease

epidemiology

Intervention Type OTHER

Relative prevalence of different chronic respiratory disease phenotypes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

epidemiology

Relative prevalence of different chronic respiratory disease phenotypes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: ≥ 18 years old
* Gender: Female and Male
* Signed informed consent
* Out-patients at the Pham Ngoc Thach Hospital
* One or several symptoms suggesting chronic respiratory disease (cough, chest tightness, wheezing, dyspnoea, sputum), lasting 3 months or more.
* Lung function defect (FEV1/FVC \< 0,7 or FEV1 \< 80% PV with FEV1/FVC \> 0,7 or FEV1\> 80% PV and FEV1/FVC \> 0,7 with a decrease of DLCO (\< 80% PV).

FEV1: Forced Expiratory Volume in 1 Second FVC : Forced Vital Capacity PV: predicted value DLCO: Diffusing Capacity of the Lung for Carbon Monoxide

* Patients are able to stop anti-histamine 5 days before evaluation.
* Patients are able to stop bronchodilator treatment before performing lung function test according to standard practice (immediate release theophylline: 24 hours, long acting β2-agonist: 12 hours, short acting β2-agonist: 6 hours and short acting anticholinergic: 8 hours).

Exclusion Criteria

* The patients do not agree to participate in the study.
* Presence of one or more chronic diseases: HIV, active tuberculosis, hypertension, heart failure, diabetes, low BMI (\<18.5) or mental health disorders.
* Treatment with B-blockers, drugs of vascular/heart disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No